Disclosure under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.9%1-day move

₹1719.00

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-1.9+0.6+0.7-0.5+0.1+6.5+22.6+19.4+35.8+59.0

Up moveDown movePending

AI summary

Fredun Pharmaceuticals has disclosed that its Managing Director and CFO, Fredun Nariman Medhora, increased his equity stake in the company through a preferential allotment arising from the conversion of warrants. He was allotted 1,06,668 equity shares valued at approximately Rs. 13.33 crore on 25 March 2026, with the intimation made on 26 March 2026. As a result, his shareholding rose from 1,79,672 shares (3.35%) to 2,86,340 shares (5.23%). The disclosure was filed in Form C under SEBI's insider trading regulations as a continual disclosure of change in holding by a promoter/director.

Likely market impact

This is a promoter/director-led stake increase via warrant conversion, which signals insider confidence in the company's prospects. Higher promoter ownership is generally viewed positively by retail investors and may support the stock sentiment.